189 related articles for article (PubMed ID: 33309058)
1. Amphotericin B induces epithelial voltage responses in people with cystic fibrosis.
Chorghade RS; Kim BR; Launspach JL; Karp PH; Welsh MJ; Burke MD
J Cyst Fibros; 2021 May; 20(3):540-550. PubMed ID: 33309058
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule ion channels increase host defences in cystic fibrosis airway epithelia.
Muraglia KA; Chorghade RS; Kim BR; Tang XX; Shah VS; Grillo AS; Daniels PN; Cioffi AG; Karp PH; Zhu L; Welsh MJ; Burke MD
Nature; 2019 Mar; 567(7748):405-408. PubMed ID: 30867598
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory cytokines TNF-α and IL-17 enhance the efficacy of cystic fibrosis transmembrane conductance regulator modulators.
Rehman T; Karp PH; Tan P; Goodell BJ; Pezzulo AA; Thurman AL; Thornell IM; Durfey SL; Duffey ME; Stoltz DA; McKone EF; Singh PK; Welsh MJ
J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34166230
[TBL] [Abstract][Full Text] [Related]
4. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations.
Mutyam V; Du M; Xue X; Keeling KM; White EL; Bostwick JR; Rasmussen L; Liu B; Mazur M; Hong JS; Falk Libby E; Liang F; Shang H; Mense M; Suto MJ; Bedwell DM; Rowe SM
Am J Respir Crit Care Med; 2016 Nov; 194(9):1092-1103. PubMed ID: 27104944
[TBL] [Abstract][Full Text] [Related]
6. Human cystic fibrosis airway epithelia have reduced Cl- conductance but not increased Na+ conductance.
Itani OA; Chen JH; Karp PH; Ernst S; Keshavjee S; Parekh K; Klesney-Tait J; Zabner J; Welsh MJ
Proc Natl Acad Sci U S A; 2011 Jun; 108(25):10260-5. PubMed ID: 21646513
[TBL] [Abstract][Full Text] [Related]
7. Resveratrol and ivacaftor are additive G551D CFTR-channel potentiators: therapeutic implications for cystic fibrosis sinus disease.
Cho DY; Zhang S; Lazrak A; Grayson JW; Peña Garcia JA; Skinner DF; Lim DJ; Mackey C; Banks C; Matalon S; Woodworth BA
Int Forum Allergy Rhinol; 2019 Jan; 9(1):100-105. PubMed ID: 30152192
[TBL] [Abstract][Full Text] [Related]
8. Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence.
Kotha K; Clancy JP
Ther Adv Respir Dis; 2013 Oct; 7(5):288-96. PubMed ID: 24004658
[TBL] [Abstract][Full Text] [Related]
9. Relationships among CFTR expression, HCO3- secretion, and host defense may inform gene- and cell-based cystic fibrosis therapies.
Shah VS; Ernst S; Tang XX; Karp PH; Parker CP; Ostedgaard LS; Welsh MJ
Proc Natl Acad Sci U S A; 2016 May; 113(19):5382-7. PubMed ID: 27114540
[TBL] [Abstract][Full Text] [Related]
10. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
11. Medical reversal of chronic sinusitis in a cystic fibrosis patient with ivacaftor.
Chang EH; Tang XX; Shah VS; Launspach JL; Ernst SE; Hilkin B; Karp PH; Abou Alaiwa MH; Graham SM; Hornick DB; Welsh MJ; Stoltz DA; Zabner J
Int Forum Allergy Rhinol; 2015 Feb; 5(2):178-81. PubMed ID: 25363320
[TBL] [Abstract][Full Text] [Related]
12. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist.
Lee SE; Farzal Z; Daniels MLA; Thorp BD; Zanation AM; Senior BA; Ebert CS; Kimple AJ
Am J Rhinol Allergy; 2020 Jul; 34(4):573-580. PubMed ID: 32168995
[TBL] [Abstract][Full Text] [Related]
13. Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor.
Xue X; Mutyam V; Tang L; Biswas S; Du M; Jackson LA; Dai Y; Belakhov V; Shalev M; Chen F; Schacht J; J Bridges R; Baasov T; Hong J; Bedwell DM; Rowe SM
Am J Respir Cell Mol Biol; 2014 Apr; 50(4):805-16. PubMed ID: 24251786
[TBL] [Abstract][Full Text] [Related]
14. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study.
Sermet-Gaudelus I; Renouil M; Fajac A; Bidou L; Parbaille B; Pierrot S; Davy N; Bismuth E; Reinert P; Lenoir G; Lesure JF; Rousset JP; Edelman A
BMC Med; 2007 Mar; 5():5. PubMed ID: 17394637
[TBL] [Abstract][Full Text] [Related]
15. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
16. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel.
Wu YS; Jiang J; Ahmadi S; Lew A; Laselva O; Xia S; Bartlett C; Ip W; Wellhauser L; Ouyang H; Gonska T; Moraes TJ; Bear CE
Mol Pharmacol; 2019 Oct; 96(4):515-525. PubMed ID: 31427400
[TBL] [Abstract][Full Text] [Related]
17. Correlating genotype with phenotype using CFTR-mediated whole-cell Cl
Noel S; Servel N; Hatton A; Golec A; Rodrat M; Ng DRS; Li H; Pranke I; Hinzpeter A; Edelman A; Sheppard DN; Sermet-Gaudelus I
J Physiol; 2022 Mar; 600(6):1515-1531. PubMed ID: 34761808
[TBL] [Abstract][Full Text] [Related]
18. The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy.
Lommatzsch ST; Taylor-Cousar JL
Ther Adv Respir Dis; 2019; 13():1753466619844424. PubMed ID: 31027466
[TBL] [Abstract][Full Text] [Related]
19. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis.
Clancy JP; Bebök Z; Ruiz F; King C; Jones J; Walker L; Greer H; Hong J; Wing L; Macaluso M; Lyrene R; Sorscher EJ; Bedwell DM
Am J Respir Crit Care Med; 2001 Jun; 163(7):1683-92. PubMed ID: 11401894
[TBL] [Abstract][Full Text] [Related]
20. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
